Multicenter, Open Label, Randomized and Parallel Group Phase IV Pilot Study Evaluating the Effectiveness of Functional Rehabilitation Protocol in RRMS Patients Treated With Betaferon®

NCT00780455 Phase 4 TERMINATED Results posted

Studying the effectiveness of a functional rehabilitation protocol (FRP) in early Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with Betaferon by comparing the physical ability of patients with and without FRP.

Details

Lead sponsor	Bayer
Phase	Phase 4
Status	TERMINATED
Enrolment	4
Start date	2008-10
Completion	2009-09

Conditions

• Multiple Sclerosis, Relapsing-Remitting

Interventions

• Interferon beta-1b, FRP within 15 days after randomization
• Interferon beta-1b, FRP about 6 weeks after randomization

Primary outcomes

• Total Walking Area (in Covered Meters) Either After 6 Minute or at the Time of the Premature Stop of the Test. — Up to 6 minutes
• Time of Discomfort Appearance — Up to 6 minutes
• Distance of Discomfort Appearance — Up to 6 minutes
• Rhythm Change During 6 Minutes Walking Test — Up to 6 minutes

Countries

France